Literature DB >> 26877262

Neuropilin 1 Receptor Is Up-Regulated in Dysplastic Epithelium and Oral Squamous Cell Carcinoma.

Shokoufeh Shahrabi-Farahani1, Marina Gallottini2, Fabiana Martins2, Erik Li1, Dayna R Mudge3, Hironao Nakayama4, Kyoko Hida5, Dipak Panigrahy6, Patricia A D'Amore7, Diane R Bielenberg8.   

Abstract

Neuropilins are receptors for disparate ligands, including proangiogenic factors such as vascular endothelial growth factor and inhibitory class 3 semaphorin (SEMA3) family members. Differentiated cells in skin epithelium and cutaneous squamous cell carcinoma highly express the neuropilin-1 (NRP1) receptor. We examined the expression of NRP1 in human and mouse oral mucosa. NRP1 was significantly up-regulated in oral epithelial dysplasia and oral squamous cell carcinoma (OSCC). NRP1 receptor localized to the outer suprabasal epithelial layers in normal tongue, an expression pattern similar to the normal skin epidermis. However, dysplastic tongue epithelium and OSCC up-regulated NRP1 in basal and proliferating epithelial layers, a profile unseen in cutaneous squamous cell carcinoma. NRP1 up-regulation is observed in a mouse carcinogen-induced OSCC model and in human tongue OSCC biopsies. Human OSCC cell lines express NRP1 protein in vitro and in mouse tongue xenografts. Sites of capillary infiltration into orthotopic OSCC tumors correlate with high NRP1 expression. HSC3 xenografts, which express the highest NRP1 levels of the cell lines examined, showed massive intratumoral lymphangiogenesis. SEMA3A inhibited OSCC cell migration, suggesting that the NRP1 receptor was bioactive in OSCC. In conclusion, NRP1 is regulated in the oral epithelium and is selectively up-regulated during epithelial dysplasia. NRP1 may function as a reservoir to sequester proangiogenic ligands within the neoplastic compartment, thereby recruiting neovessels toward tumor cells.
Copyright © 2016 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26877262      PMCID: PMC4822338          DOI: 10.1016/j.ajpath.2015.11.021

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  51 in total

1.  Characteristics of oral mucosal events related to bevacizumab treatment.

Authors:  Igor T Gavrilovic; Yevgeniy Balagula; Alyx C Rosen; Vijay Ramaswamy; Maura N Dickler; Ira J Dunkel; Mario E Lacouture
Journal:  Oncologist       Date:  2012-01-26

2.  Identification of a natural soluble neuropilin-1 that binds vascular endothelial growth factor: In vivo expression and antitumor activity.

Authors:  M L Gagnon; D R Bielenberg; Z Gechtman; H Q Miao; S Takashima; S Soker; M Klagsbrun
Journal:  Proc Natl Acad Sci U S A       Date:  2000-03-14       Impact factor: 11.205

3.  Experimental study of antiangiogenic gene therapy targeting VEGF in oral cancer.

Authors:  Yasuo Okada; Hikaru Ueno; Masataka Katagiri; Takahiro Oneyama; Kana Shimomura; Satoshi Sakurai; Izumi Mataga; Michiko Moride; Hitoshi Hasegawa
Journal:  Odontology       Date:  2010-02-16       Impact factor: 2.634

4.  Neuropilin-1 expression in cancer and development.

Authors:  Adrian M Jubb; Laura A Strickland; Scot D Liu; Judy Mak; Maike Schmidt; Hartmut Koeppen
Journal:  J Pathol       Date:  2011-10-25       Impact factor: 7.996

5.  Neuropilin-1 is expressed by endothelial and tumor cells as an isoform-specific receptor for vascular endothelial growth factor.

Authors:  S Soker; S Takashima; H Q Miao; G Neufeld; M Klagsbrun
Journal:  Cell       Date:  1998-03-20       Impact factor: 41.582

Review 6.  Neuropilin signalling in vessels, neurons and tumours.

Authors:  Claudio Raimondi; Christiana Ruhrberg
Journal:  Semin Cell Dev Biol       Date:  2013-01-11       Impact factor: 7.727

7.  Semaphorin-3A and semaphorin-3F work together to repel endothelial cells and to inhibit their survival by induction of apoptosis.

Authors:  Noga Guttmann-Raviv; Niva Shraga-Heled; Asya Varshavsky; Cinthya Guimaraes-Sternberg; Ofra Kessler; Gera Neufeld
Journal:  J Biol Chem       Date:  2007-06-14       Impact factor: 5.157

8.  Tumorigenic keratinocyte lines requiring anchorage and fibroblast support cultured from human squamous cell carcinomas.

Authors:  J G Rheinwald; M A Beckett
Journal:  Cancer Res       Date:  1981-05       Impact factor: 12.701

9.  VEGF-A/NRP1 stimulates GIPC1 and Syx complex formation to promote RhoA activation and proliferation in skin cancer cells.

Authors:  Ayumi Yoshida; Akio Shimizu; Hirotsugu Asano; Tetsuya Kadonosono; Shinae Kizaka Kondoh; Elena Geretti; Akiko Mammoto; Michael Klagsbrun; Misuzu Kurokawa Seo
Journal:  Biol Open       Date:  2015-07-24       Impact factor: 2.422

10.  Identification of genes regulating migration and invasion using a new model of metastatic prostate cancer.

Authors:  Jacqueline Banyard; Ivy Chung; Matthew Migliozzi; Derek T Phan; Arianne M Wilson; Bruce R Zetter; Diane R Bielenberg
Journal:  BMC Cancer       Date:  2014-05-30       Impact factor: 4.430

View more
  3 in total

1.  NRP-1 interacts with GIPC1 and α6/β4-integrins to increase YAP1/∆Np63α-dependent epidermal cancer stem cell survival.

Authors:  Daniel Grun; Gautam Adhikary; Richard L Eckert
Journal:  Oncogene       Date:  2018-05-14       Impact factor: 9.867

2.  Neuropilin-1 contributes to esophageal squamous cancer progression via promoting P65-dependent cell proliferation.

Authors:  F Shi; L Shang; L-Y Yang; Y-Y Jiang; X-M Wang; J-J Hao; Y Zhang; D-K Huang; Y Cai; X Xu; Q-M Zhan; X-M Jia; Y Cao; M-R Wang
Journal:  Oncogene       Date:  2017-10-23       Impact factor: 9.867

Review 3.  COVID-19 and Dentistry in 72 Questions: An Overview of the Literature.

Authors:  Stéphane Derruau; Jérôme Bouchet; Ali Nassif; Alexandre Baudet; Kazutoyo Yasukawa; Sandrine Lorimier; Isabelle Prêcheur; Agnès Bloch-Zupan; Bernard Pellat; Hélène Chardin; Sophie Jung
Journal:  J Clin Med       Date:  2021-02-16       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.